An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's ...

An update on the first clinical trial evaluating a pluripotent stem cell-derived neural stem cell therapy for Huntington's disease was presented today at the ISSCR 2026 Annual Meeting.

Western researcher Patrick O’Donoghue advances Huntington’s disease research with tRNA-based strategies to suppress toxic proteins and improve treatments.

The Swiss pharmaceutical giant told patient groups tominersen didn't delay disease progression in one trial, while a study of ...

A study conducted by the Sant Pau Research Institute (IR Sant Pau) and Hospital de Sant Pau has identified for the first time ...

An update on the first clinical trial evaluating a pluripotent stem cell‑derived neural stem cell therapy for Huntington’s ...

Researchers have made an important Huntington's disease discovery. They have found that the protein mutated in patients with Huntington's disease doesn't repair DNA as intended, impacting the ability ...

The hereditary disorder Huntington's disease has so far been considered incurable. Its clinical manifestations include ...

A drug has blocked the brain process that kills cells in incurable Huntington's disease—and works in human cells.

Megan covers the intersection of science and society. How is biomedical research funded? Who benefits? And how do new technologies reflect and shape our values? You can reach Megan on Signal at ...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington's ...

IXICO plc (LSE:IXI) has maintained its upgraded revenue guidance for 2026 and 2027 despite the cancellation of two Huntington ...